The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma.
Ardeshna (2005)
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensBr J Haematol, 130
Seshadri (2008)
Salvage therapy for relapsed/refractory diffuse large B cell lymphomaBiol Blood Marrow Transplant, 14
Linch (1993)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialLancet, 341
Cheson (1999)
NCI Sponsored International Working GroupJ Clin Oncol, 17
Fisher (1993)
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomaN Engl J Med, 328
Philip (1995)
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphomaN Engl J Med, 333
Stiff (2013)
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaN Engl J Med, 369
The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma.
Experimental and Clinical Transplantation – Pubmed
Published: Feb 27, 2024
Access the full text.
Sign up today, get DeepDyve free for 14 days.